メタボリック症候群における高血圧の管理 (特集 メタボリックシンドロームの克服に向けて)  [in Japanese] Control of hypertension in metabolic syndrome  [in Japanese]

Access this Article

Abstract

Metabolic syndrome includes abdominal obesity, hyperlipidemia, diabetes, and hypertension. All, but hypertension, are obviously related to metabolism. However, hypertension might result from, at least in part, abdominal obesity, because adipose tissue produces bioactive mediators (adipocytokines)which increase blood pressure. In treatment of hypertension, we should concern insulin resistance, which is a major risk factor of cardiovascular events. Angiotensin converting enzyme inhibitor is known to improve insulin resistance, but results of angiotensin receptor blocker in animal studies are controversial. In clinical trial, there are many established data that ARBs prevent new onset of diabetes mellitus, suggesting that this agent also has a beneficial effect on glucose metabolism. Short acting Ca-antagonists, such as nifedipine, decrease insulin sensitivity, but long-acting Ca-antagonists increase it. βblockers decrease insulin sensitivity but those with α-blocking action improve insulin resistance. Recent study, ARB is more potent to reduce cardiovascular risk in those with obesity than in those with normal body weight, suggesting some drugs are more effective in metabolic syndrome. Thus, when we chose antihypertensive drugs in treating patients with metabolic syndrome, we have to choose proper drugs in addition to modify life-style.

Journal

  • Shikoku acta medica

    Shikoku acta medica 63(3・4), 97-100, 2007-08-25

    徳島医学会

Codes

  • NII Article ID (NAID)
    120006334162
  • NII NACSIS-CAT ID (NCID)
    AN00102041
  • Text Lang
    JPN
  • Article Type
    特集
  • Journal Type
    大学紀要
  • ISSN
    00373699
  • NDL Article ID
    8951913
  • NDL Source Classification
    ZS7(科学技術--医学)
  • NDL Call No.
    Z19-344
  • Data Source
    NDL  IR 
Page Top